Sarepta Therapeutics, Inc. (0L35.L)
USD 122.56
(-2.47%)
USD 122.56
(-2.47%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.26 Billion USD | 4.35% |
| 2022 | 3.12 Billion USD | -0.62% |
| 2021 | 3.14 Billion USD | 5.47% |
| 2020 | 2.98 Billion USD | 63.74% |
| 2019 | 1.82 Billion USD | 11.01% |
| 2018 | 1.64 Billion USD | 25.54% |
| 2017 | 1.3 Billion USD | 208.41% |
| 2016 | 424.1 Million USD | 54.91% |
| 2015 | 273.78 Million USD | -7.2% |
| 2014 | 295.03 Million USD | 1.19% |
| 2013 | 291.56 Million USD | 42.23% |
| 2012 | 204.99 Million USD | 277.05% |
| 2011 | 54.36 Million USD | 18.25% |
| 2010 | 45.97 Million USD | -23.41% |
| 2009 | 60.02 Million USD | 135.07% |
| 2008 | 25.53 Million USD | -33.91% |
| 2007 | 38.63 Million USD | -5.44% |
| 2006 | 40.86 Million USD | -27.56% |
| 2005 | 56.4 Million USD | 97.79% |
| 2004 | 28.51 Million USD | -39.51% |
| 2003 | 47.14 Million USD | 64.82% |
| 2002 | 28.6 Million USD | -15.41% |
| 2001 | 33.81 Million USD | -3.63% |
| 2000 | 35.08 Million USD | 172.0% |
| 1999 | 12.9 Million USD | 26.47% |
| 1998 | 10.2 Million USD | -45.74% |
| 1997 | 18.8 Million USD | 347.62% |
| 1996 | 4.2 Million USD | 82.61% |
| 1995 | 2.3 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.22 Billion USD | -1.23% |
| 2024 Q2 | 3.42 Billion USD | 6.2% |
| 2023 Q1 | 3.05 Billion USD | -2.19% |
| 2023 FY | 3.26 Billion USD | 4.35% |
| 2023 Q4 | 3.26 Billion USD | 4.98% |
| 2023 Q3 | 3.1 Billion USD | -0.52% |
| 2023 Q2 | 3.12 Billion USD | 2.16% |
| 2022 Q2 | 2.99 Billion USD | -1.94% |
| 2022 Q3 | 3.15 Billion USD | 5.32% |
| 2022 Q4 | 3.12 Billion USD | -0.88% |
| 2022 FY | 3.12 Billion USD | -0.62% |
| 2022 Q1 | 3.05 Billion USD | -2.92% |
| 2021 Q4 | 3.14 Billion USD | 18.25% |
| 2021 Q1 | 2.76 Billion USD | -7.35% |
| 2021 Q2 | 2.75 Billion USD | -0.22% |
| 2021 Q3 | 2.66 Billion USD | -3.51% |
| 2021 FY | 3.14 Billion USD | 5.47% |
| 2020 Q3 | 2.78 Billion USD | -3.55% |
| 2020 FY | 2.98 Billion USD | 63.74% |
| 2020 Q2 | 2.88 Billion USD | -2.18% |
| 2020 Q4 | 2.98 Billion USD | 7.34% |
| 2020 Q1 | 2.94 Billion USD | 61.69% |
| 2019 FY | 1.82 Billion USD | 11.01% |
| 2019 Q2 | 1.74 Billion USD | -11.01% |
| 2019 Q3 | 1.7 Billion USD | -2.59% |
| 2019 Q4 | 1.82 Billion USD | 7.07% |
| 2019 Q1 | 1.96 Billion USD | 19.6% |
| 2018 FY | 1.64 Billion USD | 25.54% |
| 2018 Q2 | 1.24 Billion USD | -4.09% |
| 2018 Q1 | 1.3 Billion USD | -0.59% |
| 2018 Q3 | 1.18 Billion USD | -5.15% |
| 2018 Q4 | 1.64 Billion USD | 38.82% |
| 2017 Q2 | 450.13 Million USD | -12.0% |
| 2017 Q1 | 511.53 Million USD | 20.61% |
| 2017 FY | 1.3 Billion USD | 208.41% |
| 2017 Q4 | 1.3 Billion USD | 63.44% |
| 2017 Q3 | 800.28 Million USD | 77.79% |
| 2016 Q1 | 213.36 Million USD | -22.07% |
| 2016 Q2 | 204.06 Million USD | -4.36% |
| 2016 Q3 | 487.31 Million USD | 138.8% |
| 2016 FY | 424.1 Million USD | 54.91% |
| 2016 Q4 | 424.1 Million USD | -12.97% |
| 2015 FY | 273.78 Million USD | -7.2% |
| 2015 Q3 | 184.75 Million USD | -20.27% |
| 2015 Q2 | 231.71 Million USD | -4.53% |
| 2015 Q1 | 242.7 Million USD | -17.74% |
| 2015 Q4 | 273.78 Million USD | 48.19% |
| 2014 FY | 295.03 Million USD | 1.19% |
| 2014 Q2 | 337.3 Million USD | 22.48% |
| 2014 Q3 | 319.05 Million USD | -5.41% |
| 2014 Q4 | 295.03 Million USD | -7.53% |
| 2014 Q1 | 275.38 Million USD | -5.55% |
| 2013 FY | 291.56 Million USD | 42.23% |
| 2013 Q3 | 304.47 Million USD | 65.81% |
| 2013 Q2 | 183.63 Million USD | -5.02% |
| 2013 Q1 | 193.34 Million USD | -5.68% |
| 2013 Q4 | 291.56 Million USD | -4.24% |
| 2012 Q4 | 204.99 Million USD | 286.18% |
| 2012 Q3 | 53.08 Million USD | 26.08% |
| 2012 Q2 | 42.1 Million USD | -9.75% |
| 2012 Q1 | 46.64 Million USD | -14.2% |
| 2012 FY | 204.99 Million USD | 277.05% |
| 2011 Q1 | 47.03 Million USD | 2.29% |
| 2011 Q2 | 74.93 Million USD | 59.33% |
| 2011 Q3 | 61.08 Million USD | -18.48% |
| 2011 Q4 | 54.36 Million USD | -10.99% |
| 2011 FY | 54.36 Million USD | 18.25% |
| 2010 Q1 | 52.82 Million USD | -12.0% |
| 2010 FY | 45.97 Million USD | -23.41% |
| 2010 Q3 | 50.86 Million USD | 4.51% |
| 2010 Q4 | 45.97 Million USD | -9.6% |
| 2010 Q2 | 48.66 Million USD | -7.87% |
| 2009 Q3 | 65.12 Million USD | 99.66% |
| 2009 Q4 | 60.02 Million USD | -7.83% |
| 2009 Q2 | 32.61 Million USD | -11.89% |
| 2009 Q1 | 37.01 Million USD | 44.96% |
| 2009 FY | 60.02 Million USD | 135.07% |
| 2008 Q2 | 32.57 Million USD | -8.18% |
| 2008 Q1 | 35.47 Million USD | -8.17% |
| 2008 Q4 | 25.53 Million USD | -13.48% |
| 2008 Q3 | 29.51 Million USD | -9.4% |
| 2008 FY | 25.53 Million USD | -33.91% |
| 2007 Q2 | 31.2 Million USD | -11.61% |
| 2007 Q4 | 38.63 Million USD | 43.82% |
| 2007 FY | 38.63 Million USD | -5.44% |
| 2007 Q1 | 35.3 Million USD | -13.6% |
| 2007 Q3 | 26.86 Million USD | -13.92% |
| 2006 Q4 | 40.86 Million USD | -12.2% |
| 2006 Q3 | 46.54 Million USD | -11.15% |
| 2006 Q1 | 58.11 Million USD | 3.03% |
| 2006 FY | 40.86 Million USD | -27.56% |
| 2006 Q2 | 52.38 Million USD | -9.87% |
| 2005 Q3 | 39.51 Million USD | -2.53% |
| 2005 Q1 | 45.69 Million USD | 60.24% |
| 2005 Q4 | 56.4 Million USD | 42.75% |
| 2005 FY | 56.4 Million USD | 97.79% |
| 2005 Q2 | 40.54 Million USD | -11.28% |
| 2004 Q4 | 28.51 Million USD | -11.91% |
| 2004 FY | 28.51 Million USD | -39.51% |
| 2004 Q2 | 38.14 Million USD | -16.72% |
| 2004 Q3 | 32.37 Million USD | -15.12% |
| 2004 Q1 | 45.8 Million USD | -2.85% |
| 2003 FY | 47.14 Million USD | 64.82% |
| 2003 Q4 | 47.14 Million USD | 27.02% |
| 2003 Q3 | 37.11 Million USD | -6.33% |
| 2003 Q2 | 39.62 Million USD | 85.74% |
| 2003 Q1 | 21.33 Million USD | -25.42% |
| 2002 Q2 | 37.53 Million USD | -16.85% |
| 2002 FY | 28.6 Million USD | -15.41% |
| 2002 Q1 | 45.13 Million USD | 33.48% |
| 2002 Q3 | 30.74 Million USD | -18.09% |
| 2002 Q4 | 28.6 Million USD | -6.96% |
| 2001 Q4 | 33.81 Million USD | 2.04% |
| 2001 Q1 | 30.45 Million USD | -13.2% |
| 2001 Q3 | 33.14 Million USD | -15.83% |
| 2001 Q2 | 39.37 Million USD | 29.28% |
| 2001 FY | 33.81 Million USD | -3.63% |
| 2000 Q1 | 15.79 Million USD | 22.41% |
| 2000 Q3 | 40.01 Million USD | 222.0% |
| 2000 Q2 | 12.42 Million USD | -21.31% |
| 2000 FY | 35.08 Million USD | 172.0% |
| 2000 Q4 | 35.08 Million USD | -12.31% |
| 1999 FY | 12.9 Million USD | 26.47% |
| 1999 Q1 | 8 Million USD | -21.57% |
| 1999 Q4 | 12.9 Million USD | 239.47% |
| 1999 Q2 | 5.7 Million USD | -28.75% |
| 1999 Q3 | 3.8 Million USD | -33.33% |
| 1998 Q2 | 15.8 Million USD | -9.71% |
| 1998 Q3 | 12.6 Million USD | -20.25% |
| 1998 FY | 10.2 Million USD | -45.74% |
| 1998 Q1 | 17.5 Million USD | -6.91% |
| 1998 Q4 | 10.2 Million USD | -19.05% |
| 1997 Q3 | 19.4 Million USD | 4.86% |
| 1997 Q2 | 18.5 Million USD | 400.0% |
| 1997 FY | 18.8 Million USD | 347.62% |
| 1997 Q1 | 3.7 Million USD | -11.9% |
| 1997 Q4 | 18.8 Million USD | -3.09% |
| 1996 FY | 4.2 Million USD | 82.61% |
| 1996 Q4 | 4.2 Million USD | 0.0% |
| 1995 FY | 2.3 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | -554.023% |
| Dynavax Technologies Corporation | 997.09 Million USD | -227.408% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -131.698% |
| Perrigo Company plc | 10.8 Billion USD | 69.798% |
| Illumina, Inc. | 10.11 Billion USD | 67.713% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 96.693% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -318.347% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 95.971% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 87.764% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -1367.186% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 90.131% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -4869.67% |
| Waters Corporation | 4.62 Billion USD | 29.443% |
| Biogen Inc. | 26.84 Billion USD | 87.839% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -1874.701% |
| Evolus, Inc. | 188.99 Million USD | -1627.307% |
| Adicet Bio, Inc. | 207.29 Million USD | -1474.846% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -2494.145% |
| bluebird bio, Inc. | 619.16 Million USD | -427.258% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -1486.317% |
| FibroGen, Inc. | 423.52 Million USD | -670.803% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 69.669% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -11446.868% |
| Homology Medicines, Inc. | 47.05 Million USD | -6837.493% |
| Geron Corporation | 394.07 Million USD | -728.413% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 14.76% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -319.676% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -172.343% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -785.933% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -150.933% |
| Zoetis Inc. | 14.28 Billion USD | 77.148% |
| Abeona Therapeutics Inc. | 64 Million USD | -5000.741% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 2.711% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 52.283% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 85.638% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -5734.914% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -9.181% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -1872.506% |
| Verastem, Inc. | 149.71 Million USD | -2080.483% |
| Nektar Therapeutics | 398.03 Million USD | -720.177% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -454.977% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -1553.745% |
| OPKO Health, Inc. | 2.01 Billion USD | -62.28% |
| Exelixis, Inc. | 2.94 Billion USD | -10.951% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -0.405% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -425.259% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -2014.554% |
| uniQure N.V. | 831.68 Million USD | -292.524% |
| Imunon, Inc. | 21.91 Million USD | -14794.451% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -211.134% |
| Insmed Incorporated | 1.32 Billion USD | -145.487% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -88.348% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -248.363% |
| TG Therapeutics, Inc. | 329.58 Million USD | -890.505% |
| Incyte Corporation | 6.78 Billion USD | 51.865% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -77.916% |